Welcome to our dedicated page for Silvaco Group SEC filings (Ticker: SVCO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Silvaco Group's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Silvaco Group's regulatory disclosures and financial reporting.
Candace Jackson, SVP, General Counsel and Corporate Secretary of Silvaco Group, Inc. (SVCO), reported a routine share disposition on 10/01/2025 to satisfy tax withholding tied to the vesting of restricted stock units. The filing shows 2,510 shares of common stock were withheld at a price of $5.44, leaving her with 51,369 shares beneficially owned after the transaction. The transaction is coded F, which the filer explains represents shares withheld by the issuer to cover tax obligations arising from RSU vesting. This is an administrative, non-sales transfer rather than an open-market sale and does not indicate an active cash divestiture by the reporting person.
Silvaco Group, Inc. (SVCO) director Anthony K.K. Ngai reported multiple open-market purchases of common stock across 09/08/2025–09/11/2025 totaling 11,700 shares. Transaction prices ranged from $5.1561 to $5.3375, and the filing shows 80,777 shares beneficially owned after the last reported purchase. The Form 4 is signed by an attorney-in-fact and lists the reporter as a director filing individually.
Silvaco Group, Inc. announced that Christopher Zegarelli will join as Chief Financial Officer effective September 15, 2025. His base salary is $450,000 and he is eligible for a $400,000 sign-on bonus paid in two $200,000 installments, the first payable within 30 days of the start date and subject to repayment if he voluntarily resigns or is terminated for cause before January 1, 2027. The second installment is contingent on achieving fiscal 2026 revenue and profit targets at or above 100% of plan and continued service through December 31, 2026. He is eligible for an annual incentive target equal to 60% of base salary, prorated for 2025, with payment based on company-wide performance and at the Board's discretion. He will receive RSUs equal to $2,300,000 in value with 1/4 vesting after one year and the balance vesting quarterly to fully vest at year four. He is eligible for the Executive Severance Plan and an indemnification agreement. The company disclosed the appointment via a press release furnished as Exhibit 99.1.
Silvaco Group, Inc. reported a CEO transition and related compensation arrangements. Dr. Babak A. Taheri stepped down as CEO and director, effective August 19, 2025, and entered a Separation Agreement providing severance and other benefits. Under that agreement he will receive aggregate cash severance of $975,484 (equal to 18 months' base salary plus pro‑rata target bonus), COBRA health benefit payments for 15 months, accelerated vesting of 126,161 unvested time‑based restricted stock units, 12 months of car lease payments totaling $12,000, and payment of a $20,000 life insurance premium. The agreement also preserves confidentiality, non‑disparagement and non‑solicit covenants and includes a release of claims.
The Board appointed Dr. Walden C. Rhines as CEO, effective August 19, 2025, and the company entered an employment agreement through March 31, 2027. Dr. Rhines will receive an annual base salary of $160,000 and may receive performance‑based restricted stock unit grants with grant‑date fair values ranging from $100,000 up to an aggregate of $6,252,636, vesting upon achievement of specified VWAP trading thresholds and continued employment through the Term. If terminated under certain conditions before or at the end of the Term, Dr. Rhines may be eligible for a lump sum severance ranging from $500,000 to $1,000,000 and accelerated vesting of PRSUs, subject to a release and covenant compliance.
Form 4 summary: Taheri Babak A., listed as Chief Executive Officer and Director of Silvaco Group, Inc. (SVCO), reported a change in beneficial ownership on 08/13/2025. The filing shows a disposition of 9,155 shares of common stock at a price of $4.65 per share under transaction code F. The filing explains these shares were withheld by the issuer to satisfy tax withholding obligations related to the vesting of restricted stock units. After the transaction, the reporting person beneficially owned 773,157 shares on a direct basis. The form was signed by Candace Jackson as attorney-in-fact on 08/14/2025.